Ac t i o n | Pharmaron reported 1H26 revenue of Rmb7.6bn (+18% yoy) and net profit of Rmb750mn (+7% yoy or +9% excl. one-offs; or +20% yoy on a non-IFRS adjusted basis), in line with profit alert. GM slightly contracted to 32.6% from 33.7% in 1H25, reflecting USD depreciation headwind. For the same reason, OPM also lowered to 13.4% in 1H26 from 14.4%. Importantly, mgmt. raised 2026 revenue growth guidance to 15%–20% yoy from 12-18% yoy, led by both strong lab service and CDMO demand. New orders grew 30%+ yo ...